Monograph Details
|
|
Immune System
> Immunization
|
|
RABAVERT |
| Manufacturer |
|
Chiron Corporation |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Rabies vaccine, inactivated 2.5IU/mL; pwd for IM inj after reconstitution; may contain trace amounts of bovine gelatin, chicken protein, neomycin, chlortetracycline, and amphotericin B. |
| Indications |
|
Preexposure immunization and post-exposure prophylaxis of rabies. |
| Adults and Children |
|
Adults: inject into deltoid area. Small children: inject into thigh. Preexposure immunization: 3 inj of 1mL IM each on day 0, 7, and either day 21 or 28. Booster: 1 dose as needed to maintain antibody titer (see literature). Post-exposure prophylaxis: a 5-dose regimen of 1mL IM given on days 0, 3, 7, 14, and 28 (give 1st dose with human rabies immunoglobulin at a separate site). If previously immunized: 2 inj of 1mL each on days 0 and 3 (no immune globulin needed). |
| Precautions |
|
Immunocompromised: may get suboptimal response (monitor titers). Postpone preexposure immunization during acute febrile illness or infection. Egg allergy. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). |
| Interactions |
|
Immunosuppressants: may get suboptimal response. |
| Adverse Reactions |
|
Local reactions, lymphadenopathy, headache, myalgia, malaise, dizziness, neuroparalytic events, anaphylaxis. |
| How Supplied |
|
Single-dose vial—1 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
